Veopoz (pozelimab-bbfg) - Regeneron
Fabhalta (iptacopan) - Novartis
Enjaymo (sutimlimab-jome) - Sanofi
Soliris (eculizumab) - AstraZeneca
Ultomiris (ravulizumab-cwvz) - AstraZeneca
Empaveli (pegcetacoplan SC) - SOBI, Biogen
Zilbrysq (zilucoplan) - UCB
Voydeya (danicopan) - AstraZeneca
Laboratory Diagnosis of Complement-Mediated Diseases: A Practical Overview. (PubMed, J Appl Lab Med) - Oct 26, 2026 - "A well-structured complement laboratory, based on rigorous preanalytical practices and validated assays, provides diagnostic information not available from other tests. This review could serve as a practical reference for laboratory clinical biochemists building or optimizing complement diagnostics in their setting." 
Journal • Atypical Hemolytic Uremic Syndrome • Cardiovascular • Complement-mediated Rare Disorders • Glomerulonephritis • Hematological Disorders • Hereditary Angioedema • Nephrology • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases
http://www.ncbi.nlm.nih.gov/pubmed/42910908
 
Alessandra Valentini; Sergio Bernardini
 
Oct 26, 2026
 
Next